Leprosy primary prevention: Difference between revisions

Jump to navigation Jump to search
m (Changes made per Mahshid's request)
 
(One intermediate revision by one other user not shown)
Line 7: Line 7:


==Primary prevention==
==Primary prevention==
There are still [[endemic]] regions in the world deeply affected by leprosy. Due to international travels, these may be a source of the [[bacteria]] for the rest world.
There are still [[endemic]] regions in the world affected by leprosy. Due to international travels, these may be a source of the [[bacteria]] for the rest world.
There is still no adequate tool for the early detection of leprosy. [[Immunoprophylaxis]] studies in different population groups with the [[BCG vaccine]], alone or in combination with killed [[Mycobacterium leprae]] or atypical [[Mycobacteria]], have shown an [[efficacy]] of 28 to 60%. A good coverage of [[BCG vaccine]] is still a major contribution to reduce the impact of leprosy in populations.<ref name=WHO>{{cite web | title = Enhanced Global Strategy for Further Reducing the Disease Burden due to Leprosy | url = http://www.searo.who.int/entity/global_leprosy_programme/documents/enhanced_global_strategy_2011_2015_operational_guidelines.pdf }}</ref>
There is still no adequate tool for the early detection of leprosy. [[Immunoprophylaxis]] studies in different population groups with the [[BCG vaccine]], alone or in combination with killed [[Mycobacterium leprae]] or atypical [[Mycobacteria]], have shown an [[efficacy]] of 28 to 60%. A good coverage of [[BCG vaccine]] is still a major contribution to reduce the impact of leprosy in populations.<ref name=WHO>{{cite web | title = Enhanced Global Strategy for Further Reducing the Disease Burden due to Leprosy | url = http://www.searo.who.int/entity/global_leprosy_programme/documents/enhanced_global_strategy_2011_2015_operational_guidelines.pdf }}</ref>


Line 22: Line 22:
[[Category:Disease]]
[[Category:Disease]]
[[Category:Dermatology]]
[[Category:Dermatology]]
[[Category:Infectious disease]]
 
[[Category:Tropical disease]]
[[Category:Tropical disease]]
[[Category:Leprosy]]
[[Category:Leprosy]]

Latest revision as of 18:10, 18 September 2017

Leprosy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Leprosy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Leprosy primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Leprosy primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Leprosy primary prevention

CDC on Leprosy primary prevention

Leprosy primary prevention in the news

Blogs on Leprosy primary prevention

Directions to Hospitals Treating Leprosy

Risk calculators and risk factors for Leprosy primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]

Overview

Primary prevention of leprosy includes immunoprophylaxis, chemoprophylaxis and education of the populations to prevent infection by the Mycobacterium leprae.

Primary prevention

There are still endemic regions in the world affected by leprosy. Due to international travels, these may be a source of the bacteria for the rest world. There is still no adequate tool for the early detection of leprosy. Immunoprophylaxis studies in different population groups with the BCG vaccine, alone or in combination with killed Mycobacterium leprae or atypical Mycobacteria, have shown an efficacy of 28 to 60%. A good coverage of BCG vaccine is still a major contribution to reduce the impact of leprosy in populations.[1]

Chemoprophylaxis of chronic infectious diseases has also shown benefits, particularly in populations with higher risk of infection with leprosy. However, it is still early to define chemoprophylaxis as a public health measure, as more trials are needed to demonstrate safety, efficacy and cost-effectiveness of these therapies.[1]

Other important element of primary prevention is the education of populations. Immediate contacts of leprosy patients have higher risk of being infected, therefore they should be aware of the condition, its transmission and what to do to minimize this risk.[1]

References

  1. 1.0 1.1 1.2 "Enhanced Global Strategy for Further Reducing the Disease Burden due to Leprosy" (PDF).


Template:WikiDoc Sources